NCT05256537View on ClinicalTrials.gov

Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 26, 2022

Primary Completion Date

September 20, 2024

Study Completion Date

March 7, 2026

Conditions
Hematologic Neoplasms
Interventions
OTHER

Omission of the drug mycophenolate mofetil

Elimination of the immunosuppressive drug mycophenolate mofetil (MMF) from the post-transplant regimen.

Trial Locations (1)

90048

Cedars-Sinai Medical Center, Los Angeles

All Listed Sponsors
lead

Ronald Paquette

OTHER